Acrux Limited Corrects Report, Expands Portfolio
Company Announcements

Acrux Limited Corrects Report, Expands Portfolio

Acrux Limited (AU:ACR) has released an update.

Acrux Limited, a specialty pharmaceutical company, has announced an amendment to their Quarterly Activities Report for March 2024, correcting the year to date column in their financial documents. The company has also reported a positive cash flow for the quarter and launched Dapsone Gel, 5% for acne vulgaris, marking their third revenue-generating product. With additional products under FDA review and plans for more, Acrux continues to expand its revenue base and product offerings.

For further insights into AU:ACR stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskAcrux Limited Eyes Revenue Growth with New Product Launches
TipRanks Australian Auto-Generated NewsdeskAcrux Limited Announces 2024 AGM for Shareholders
TipRanks Australian Auto-Generated NewsdeskAcrux Limited Spotlights at ASX Conference
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App